Request Demo

Last update 22 Jun 2026

Exenatide

Last update 22 Jun 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Exenatide (JAN/USAN/INN), Exendin-4, Presendin

+ [19]

Target

GLP-1R

Action

agonists

Mechanism

GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic DiseaseNervous System Diseases

Active Indication

Diabetes Mellitus, Type 2Parkinson DiseaseDiabetes Mellitus

Inactive Indication

Coronary Artery DiseaseDiabetes ComplicationsDiabetes Mellitus, Type 1+ [18]

Originator Organization

Eli Lilly & Co.

Amylin Pharmaceuticals, Inc.

Active Organization

AstraZeneca ABAstraZeneca KKEli Lilly Nederland BV

+ [3]

Inactive Organization

Eli Lilly & Co.

AstraZeneca PLC

Intarcia Therapeutics, Inc.

+ [4]

License Organization

Shenyang Sunshine Pharmaceuticals Co., Ltd.

Altea Therapeutics Corp.

Invex Therapeutics Ltd.

+ [9]

Drug Highest PhaseApproved

First Approval Date

United States (28 Apr 2005),

Diabetes Mellitus, Type 2

RegulationOrphan Drug (European Union)

Structure/Sequence

Sequence Code 751

Source: *****

363

Clinical Trials associated with Exenatide

ChiCTR2600116060

/ SuspendedEarly Phase 1IIT

A Single-Center, Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects with Type 2 Diabetes Mellitus

Start Date01 Dec 2025

Sponsor / Collaborator-

CTIS2025-522796-28-00

/ Not yet recruitingPhase 2

A Multicenter, Prospective, Randomized, Open-label Phase 2b Study, with Blinded Evaluation, Comparing the Combination of Amodiaquine and Potassium Canrenoate with Either Exenatide or Glibenclamide Versus Best Medical Therapy, in Patients with Acute Ischemic Stroke

Start Date01 Dec 2025

Sponsor / Collaborator-

CTIS2024-519014-31-00

/ Not yet recruitingPhase 1IIT

Measuring the macro- and microvascular responses to LPS and exenatide

Start Date26 Feb 2025

Sponsor / Collaborator

Centre for Human Drug Research

100 Clinical Results associated with Exenatide

100 Translational Medicine associated with Exenatide

100 Patents (Medical) associated with Exenatide

3,805

Literatures (Medical) associated with Exenatide

01 Sep 2026·NEUROPHARMACOLOGY

Broad glucagon-like peptide-1 (GLP-1) receptor distribution enhances glutamatergic transmission throughout the mouse cerebellar cortex

Article

Author: Rossi, David J ; Ritchey, Caitlin R ; Peters, James H ; Peterson, BreeAnne

The gut hormone glucagon-like peptide 1 (GLP-1) is a key contributor to the controls of food intake and reward processing. GLP-1 receptors (GLP-1R) are widely expressed throughout the central nervous system where their signaling alters neuronal excitability, resulting in suppressed food intake and reward. Recent studies have shown GLP-1R expression in Purkinje cells (PCs) within the cerebellum, a region gathering increasing appreciation for its role in sensory processing and appetitive behaviors. Importantly, the cerebellum responds to feeding signals and directly projects to key mesolimbic nuclei that initiate appetitive behaviors, including food intake. What remains unknown is if GLP-1Rs are expressed in other cell types of the cerebellum and the extent to which their activation produces neurophysiological changes. Here we combined RT-qPCR, RNAscope and immunohistochemistry with functional electrophysiology to map GLP-1R expression and signaling across the lobes and cell types of the cerebellar cortex of male/female C57BL/6N mice. We found that GLP-1Rs were nearly evenly expressed across all cerebellar lobes at the level of the vermis, as well as densely expressed in the deep cerebellar nuclei. At the cellular level, we found significant GLP-1R expression in granule cells (GCs) and GC-innervating mossy fibers, in addition to the previously reported expression in the PCs. Functionally, application of the GLP-1R agonist exendin-4 increased the frequency of spontaneous glutamate release on to the majority of recorded GCs and enhanced action potential firing in PCs. Together these results demonstrate broad expression of functional GLP-1R across cerebellar lobes which enhance synaptic transmission through the cerebellar cortex.

01 Sep 2026·AMERICAN HEART JOURNAL

Serial assessment of NT-proBNP and high-sensitivity cardiac troponin with glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes: Insights from EXSCEL

Article

Author: Kittipibul, Veraprapas ; Sourij, Harald ; Welsh, Paul ; Buse, John B ; Hernandez, Adrian F ; Mentz, Robert J ; Nguyen, Maggie ; Shah, Svati H ; Holman, Rury R

BACKGROUND:

In the EXSCEL trial, exenatide did not reduce major adverse cardiovascular events (MACE), but heterogeneity of benefit and the role of cardiac biomarkers remain uncertain. We evaluated the prognostic value of baseline and 1-year changes in N-terminal pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I (cTnI), and whether baseline biomarker concentrations modified exenatide effects.

METHODS:

EXSCEL randomized 14,752 adults with type 2 diabetes to exenatide 2 mg weekly (EQW) or placebo. In a biomarker cohort, 4,292 participants had serial NT-proBNP or cTnI at baseline and 1 year. Biomarkers were log transformed and Cox models related baseline concentrations and 1-year change to MACE, all-cause mortality (ACM), cardiovascular (CV) death, hospitalization for heart failure (hHF), adjusting for clinical covariates and the alternate biomarker. Treatment interaction was tested with biomarker by treatment terms.

RESULTS:

Over median 1,480 days follow-up, 529 MACE, 310 all cause deaths, 193 CV deaths, and 157 hHF events occurred. Baseline NT-proBNP was strongly prognostic (adjusted HR per 1 integer unit 1.63 for MACE, 1.85 for ACM, 2.17 for CV death, and 2.17 for hHF; all P < .001). Baseline cTnI was also prognostic with a nonlinear pattern, with risk rising mainly above the median. Per SD rise in NT-proBNP over 1 year predicted later MACE (HR 1.85) and CV death (HR 2.81; both P < .001). Baseline NT-proBNP didn't modify treatment effects. Baseline cTnI didn't modify EQW treatment effect on MACE but lower rates of CV deaths and hHF with EQW were observed at higher cTnI concentrations.

CONCLUSIONS:

NT-proBNP and cTnI were strong prognostic markers of adverse outcomes in patients with type 2 diabetes and their 1-year increases signaled higher subsequent risk. Baseline cTnI may mark heterogeneity of EQW response, but mortality interactions are hypothesis generating and require confirmation.

01 Aug 2026·AMERICAN JOURNAL OF OPHTHALMOLOGY

Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients With Type 2 Diabetes and Diabetic Retinopathy

Article

Author: Dani, Sourbha S ; Verma, Anushka ; Ganatra, Sarju ; Patel, Tirth ; Panchal, Krisha ; Ramsey, Kathryn Moynihan ; Patel, Vahin ; Upadhyay, Jagriti ; Shah, Jui ; Makwana, Bhargav ; Ramsey, David J ; Kong, Yixin ; Khadke, Sumanth ; Vivekanandan, Suja

PURPOSE:

To evaluate the association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) use on macrovascular and microvascular outcomes in patients with type 2 diabetes (T2D) and diabetic retinopathy (DR)-a high-risk group often excluded from clinical trials.

DESIGN:

Retrospective, population-based cohort study.

PARTICIPANTS:

Adults aged ≥18 years with T2D (with hemoglobin A1c of ≥6.5%) and a pre-existing diagnosis of DR from the TriNetX research network database between January 1, 2015, and December 31, 2022.

METHODS:

The study included 173,216 adults with T2D, all of whom had DR, adjusted for baseline characteristics through propensity score matching (PSM) based on whether the individuals received at least 2 prescriptions of a GLP-1 RA (semaglutide, dulaglutide, liraglutide, exenatide, tirzepatide, or lixisenatide) at least 6 months apart.

MAIN OUTCOME MEASURES:

Cox proportional hazard regression models were used to evaluate the association between GLP-1 RAs and the risk of incident macrovascular and microvascular complications over a 2-year follow-up period.

RESULTS:

After PSM, 30,613 individuals (mean [SD] age, 61.6 [11.4] years; 53.2% were females) were prescribed GLP-1 RAs. Patients on GLP-1 RAs had a decreased risk of myocardial infarctions (MIs; hazard ratio [HR], 0.65; 95% CI, 0.61-0.69), coronary artery revascularization procedures (HR, 0.75; 95% CI, 0.67-0.84), heart failure exacerbations (HR, 0.78; 95% CI, 0.76-0.81), ischemic strokes (HR, 0.78; 95% CI, 0.74-0.83), lower extremity amputations (HR, 0.78; 95% CI, 0.69-0.88), acute kidney injuries (AKI; HR, 0.68; 95% CI, 0.66-0.71), or the need for renal replacement therapy (RRT; HR, 0.40; 95% CI, 0.36-0.43). Fewer individuals also progressed to proliferative diabetic retinopathy (HR, 0.78; 95% CI, 0.71-0.86), experienced retinal vein occlusions (RVOs; HR, 0.70; 95% CI, 0.61-0.80), or developed neovascular glaucoma (HR, 0.65; 95% CI, 0.47-0.89); no association was observed for retinal artery occlusions (RAOs; HR, 0.85; 95% CI, 0.57-1.26) or cases of non-arteritic ischemic optic neuropathy (NAION; HR, 0.88; 95% CI, 0.54-1.44).

CONCLUSIONS:

In patients with T2D and pre-existing DR, the use of GLP-1 RAs was associated with a reduced risk of major macrovascular and microvascular complications, including those directly affecting the retina. Future studies are needed to assess the extent to which GLP-1 RAs benefit long-term outcomes.

145

News (Medical) associated with Exenatide

28 May 2026

·www.businesswire.com

Ontada Study Presented at ASCO 2026 Examines Real-World Use of GLP‑1 Receptor Agonists and Survival Outcomes Across Common Cancers in U.S. Community Oncology

BOSTON--(BUSINESS WIRE)--Ontada®, a McKesson business dedicated to real-world oncology data and insights, will present a real-world observational research study in an oral presentation at the American Society of Oncology (ASCO) Annual Meeting examining GLP-1 receptor agonist (RA) utilization and overall survival outcomes among patients treated in U.S. community oncology practices. The study, titled, “GLP 1 receptor agonist utilization and survival outcomes in a large U.S. community oncology cohort,” analyzed patients diagnosed with cancer between January 2021 and October 2024, with follow-up through October 2025. Investigators identified 418 patients treated with a GLP-1 receptor agonist and 3,476 non-users, with matching by cancer type and diagnosis year to evaluate overall survival (OS) outcomes. Key Data Findings Propensity-score adjusted Cox proportional hazards models evaluated the association between GLP1 RA use and overall survival among patients diagnosed with breast, prostate, colorectal, lung, hepatocellular or renal cancer. After adjustment for confounders including age, BMI, cancer stage and type, GLP‑1 receptor agonist use was significantly associated with improved overall survival (hazard ratio 0.66; 95% CI 0.45–0.97; p = 0.0031). “While GLP-1 therapies are well established for metabolic disease, emerging preclinical and observational data suggest potential anticancer effects, yet large-scale studies investigating this association have been limited,” said Jess Paulus, ScD, vice president of Real-World Research at Ontada and presenting author of the study. “As use of these therapies continues to expand, high-quality real-world data are essential to understanding their broader impact. Our findings demonstrate the value of real-world evidence in identifying anticancer signals and helping efficiently guide future research and prioritization of prospective studies.” Study Methodology This retrospective analysis used data collected between January 2021 and October 2024, with follow‑up through October 2025, and evaluated GLP‑1 receptor agonist use, including dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, and tirzepatide. Overall survival was measured from initial cancer diagnosis to death from any cause, with methods applied to address immortal time bias. Among patients who received a GLP‑1 receptor agonist, median age was 63 years, 58% were White, and 57% had a body mass index (BMI) ≥30 kg/m². Semaglutide accounted for the majority of prescriptions (55%). By comparison, non‑users had a median age of 68 years, 58% were White, and 28% had BMI ≥30 kg/m². Most GLP‑1 users (74%) initiated therapy after initial cancer diagnosis, of whom 7% initiated after a metastatic diagnosis, with breast (27%) and prostate (13%) cancers representing the most common malignancies among this group. “At Ontada, our focus is on advancing cancer care by transforming real-world data into meaningful insights,” said Christine Davis, president, Ontada. “This research reflects Ontada’s commitment to generating high-quality, real-world evidence that helps advance how cancer is understood and treated. By studying emerging therapies within community oncology settings, we can help surface insights that inform future research and ultimately support better outcomes for patients.” Other Research & Activities at ASCO 2026 Ontada is a part of McKesson, which has a broad portfolio of oncology and multispecialty solutions and partners that provide research, insights, technologies and services that help to address barriers and improve cancer and multispecialty care. At ASCO, McKesson-supported businesses including The US Oncology Network, Ontada, and Sarah Cannon Research Institute (SCRI), are part of approximately 171 accepted abstracts and presentations. These are inclusive of oral and poster presentations, educational sessions, late-breaking studies and early-phase studies. For a comprehensive list of Ontada’s 14 accepted abstracts, visit Ontada’s ASCO 2026 site. Additionally, visit the Ontada Booth (#30123) at the McCormick Place Convention Center from May 29 – June 2 to explore the data presented at ASCO and discuss Ontada’s solutions. Expert Panel on Community Oncology During ASCO 2026 Additionally, McKesson will be participating in a thought leadership panel hosted by Endpoints News on June 3, 2026, at 12 p.m. ET, titled, “Delivering Excellence, Close to Home.” Panelists include Jason Hammonds, president of Oncology & Multispecialty for McKesson, John Schuler MD, medical director and radiation oncologist with Compass Oncology, and Dr. Patt. Register and join the panelists as they share their insights and perspectives on what is working today—and what needs to evolve—to support and strengthen community oncology as a foundational component of the cancer care ecosystem. About Ontada® Ontada is an oncology technology and insights business dedicated to transforming the fight against cancer. Part of McKesson Corporation, Ontada was founded on the belief that precise insights—delivered exactly at the point of need—can save more patients’ lives. Ontada connects the full patient journey by combining technologies used by The US Oncology Network and other community oncology providers with real-world data and research relied on by leading life sciences companies. For more information, visit ontada.com. About McKesson Oncology & Multispecialty Our Oncology & Multispecialty segment delivers a portfolio of integrated solutions that support patient care by accelerating drug development, expanding access to high-quality care close to home and ensuring life-saving therapies reach the patients who need them most. We provide practice management, technology solutions, specialty drug distribution, clinical trial and group purchasing services, along with pharmacy solutions for community-based oncology practices and multispecialty providers in retina and ophthalmology. We partner behind the scenes with healthcare providers in local communities, supporting their operations so that they can stay focused on who matters most – patients.

14 May 2026

·www.biospace.com

Kariya and NeuraLight Partner to Measure How Next-Generation GLP-1 Therapies Impact the Brain

By combining novel measures of brain function with a brain-penetrant dual GLP-1/GIP agonist program, NeuraLight and Kariya Pharmaceuticals aim to tackle one of neurodegeneration's central challenges: improving brain function COPENHAGEN, Denmark & NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)-- Kariya Pharmaceuticals , a pioneer in brain-penetrant GLP-1 therapies, and NeuraLight , the leader in developing precision brain function measures, today announced a partnership to advance brain-focused GLP-1 therapeutics. The partnership integrates NeuraLight’s precision biomarker platform into Kariya’s Phase II program for KP405, a first-in-class brain-penetrant dual GLP-1/GIP agonist in development for Parkinson’s and Alzheimer’s disease. The NeuraLight platform uses its novel brain function biomarkers to quantify the neuroprotective effect of KP405. GLP-1 receptor agonists, one of the most widely prescribed drug classes in diabetes and obesity, have drawn attention as potential treatments for Alzheimer's and Parkinson's disease driven by well-established links between metabolic dysfunction and neurodegeneration . These therapies may help restore impaired glucose metabolism and insulin signaling, reduce neuroinflammation, and support neuronal survival. Notably, GLP-1 activity is also thought to enhance glucose entry into neurons, potentially mitigating energy deficits and reducing neuronal death. Clinical evidence for GLP-1s in neurodegeneration has been mounting. The LIXIPARK trial , led by Prof. Olivier Rascol, chair of NeuraLight's Scientific Advisory Board, was the first large-scale GLP-1 trial to show superiority over placebo on motor outcomes in Parkinson's disease. The ELAD trial , published in Nature Medicine and co-authored by Kariya Chief Scientific Officer Dr. Christian Hölscher, PhD, demonstrated that Alzheimer's patients treated with liraglutide showed significantly slower cognitive decline and reduced brain atrophy. Phase III trials of semaglutide in Alzheimer's and exenatide in Parkinson's, neither of which were originally designed for brain penetration, failed to meet their primary endpoints. However, the failures clarified the path forward because they signaled that the amount of drug that reaches the brain appears to determine the amount of benefit to the patient. Taken together, these trial results suggest that a GLP-1 engineered specifically for the brain, paired with functional biomarkers that can quantify whether neuroprotection is occurring, is the logical next step in neurodegeneration therapies. KP405 is a first-in-class dual GLP-1/GIP receptor agonist engineered to cross the blood-brain barrier. Unlike existing GLP-1s designed for metabolic use, KP405 incorporates a cell-penetrating peptide that actively delivers the drug into the brain, where it activates two complementary receptor pathways to reduce neuroinflammation and protect neurons. Kariya has completed Phase I with a confirmed safety and tolerability pro is now advancing to Phase II. Under the new partnership, NeuraLight's platform will be integrated into Kariya's upcoming Phase II clinical trial to support objective, quantitative assessment of brain function. "We are thrilled to partner with NeuraLight as we advance KP405 into Phase II," said Ian Laquian, Co-Founder and CEO of Kariya Pharmaceuticals . "Pairing our drug with NeuraLight's precision biomarker platform puts KP405 in the strongest possible position to translate biological promise into clinical success for patients living with Parkinson's disease." NeuraLight’s platform provides precise, actionable measures of brain function. The platform generates valuable insights into the function of relevant neural pathways for a range of CNS indications including Parkinson's and Alzheimer's. For compounds like KP405 that are designed to protect the brain from neurodegeneration, it offers a way to directly assess whether brain function is being preserved. "Quantifying whether a neuroprotective drug is preserving brain function holds the key to unlocking GLP-1s' potential in neurodegeneration," said Edmund Ben-Ami, Co-Founder and CEO of NeuraLight . "Kariya built KP405 specifically for brain delivery. Our platform is designed to measure whether that translates to functional preservation. This partnership brings together the drug and the measurement approach the field needs." About Kariya Pharmaceuticals Kariya Pharmaceuticals is a clinical-stage biotechnology company developing brain-penetrant therapeutics to slow the progression of neurodegenerative disease. Its lead asset, KP405, is a first-in-class, brain-penetrant, dual GLP-1/GIP receptor agonist engineered to enhance cellular energetics, improve insulin signaling, and reduce neuroinflammation in Parkinson’s and Alzheimer’s disease. KP405 has demonstrated clear superiority over existing incretin analogues across multiple preclinical models of neurodegeneration, and recently completed a Phase I SAD/MAD program with a favorable safety and tolerability pro with the broader GLP-1 class. Headquartered in Copenhagen, Denmark, Kariya is now advancing KP405 into Phase II development. For more information, visit . About NeuraLight NeuraLight is a healthtech company on a mission to make brain function accurately measurable and actionable. Fusing decades of world-class neuroscience research with a breakthrough AI engine and proprietary data, the NeuraLight platform sets a new standard by quantifying core aspects of brain function at scale. NeuraLight’s technology is embedded in multiple commercial partnerships and endorsed by leading neurologists, Nobel laureates and major research foundations, establishing it as a prominent infrastructure for the future of brain health. For more information, visit . Contacts Keren Sharon Product Marketing Manager info@neuralight.ai

Phase 2Phase 1

05 May 2026

·www.biospace.com

Neuraly, Inc. Supports Phase 2 Investigator-Initiated Trial of Pegsebrenatide (NLY01) for Progressive Multiple Sclerosis

GAITHERSBURG, Md.--(BUSINESS WIRE)-- Neuraly, Inc ., a wholly owned subsidiary of D&D Pharmatech, Inc. (KOSDAQ: 347850), announced that the first patient has been dosed in a Phase 2 Investigator-Initiated Trial (IIT) evaluating pegsebrenatide (NLY01), Neuraly’s long-acting GLP1 receptor agonist, for the potential treatment of patients with multiple sclerosis (MS). Multiple sclerosis is a chronic and progressive autoimmune disease of the central nervous system (CNS) affecting more than 2.8 million people worldwide, with onset typically occurring between the ages of 20 and 40. The disease is characterized by immune-mediated inflammation of the myelin sheath, the protective covering of nerve fibers, disrupting neural signaling and ultimately leading to neurodegeneration and disability. While current therapies primarily target inflammatory activity, effective treatments addressing neurodegeneration remain limited, particularly relevant to progressive forms of MS. Pegsebrenatide is a proprietary, long-acting GLP-1 receptor agonist designed to modulate neuroinflammatory pathways and protect neurons. In preclinical studies, pegsebrenatide demonstrated the ability to inhibit neuroinflammation and slow disease progression in animal models of multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease. Clinical data from a previous Phase 2 trial in 255 patients with Parkinson’s disease suggested that treatment with pegsebrenatide may slow the progression of motor dysfunction, as measured by UPDRS Part III, with the most pronounced effects observed in patients younger than 60 years of age. Together with extensive preclinical findings, these results support the continued development of pegsebrenatide as a potential disease-modifying therapy for neurodegenerative conditions, including progressive MS. The study NCT07497399, titled “Targeting Agonists of Glucagon-like peptide-1 receptor for Multiple Sclerosis (TAG-MS): A Phase 2, Randomized, Double-Blind, Parallel-Arm Study,” will be led by Dr. Ellen Mowry, Professor of Neurology and Epidemiology at Johns Hopkins University, and will be conducted at multiple leading academic medical centers. In this randomized, placebo-controlled, double-blind study, approximately 120 patients with progressive MS will be randomized 1:1 to receive pegsebrenatide or placebo once-weekly for 96 weeks. The primary endpoint is the change from baseline in normalized brain parenchymal volume, measured by MRI, as an indicator of progressive brain atrophy and neurodegeneration. Key secondary endpoints will include changes in normalized gray matter, thalamic volumes, and cortical thickness, as well as clinical outcomes including the Expanded Disability Status Scale (EDSS) and other CNS biomarkers. “We are excited to advance the clinical development of pegsebrenatide in collaboration with leading MS research centers,” said Seulki Lee, CEO of Neuraly. “Patients with progressive MS continue to face significant unmet medical needs, with neuroinflammation playing a central role in driving disease progression. Pegsebrenatide represents a differentiated therapeutic strategy aimed at addressing the underlying neuroinflammatory processes that drive neurodegeneration. We believe this program has the potential to expand the treatment paradigm for progressive MS and other neurodegenerative diseases.” About Pegsebrenatide (NLY01) Pegsebrenatide is a proprietary long-acting analogue of exendin-4, a glucagon-like peptide-1 receptor (GLP-1R) agonist that limits neurodegeneration by suppressing neuroinflammation, thus slowing disease progression in animal models of Parkinson’s and Alzheimer’s disease and multiple sclerosis. Pegsebrenatide is being developed as a potentially disease-modifying agent for the treatment of multiple neurodegenerative disorders. About Neuraly Neuraly, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies that address the underlying causes of neurodegenerative diseases. The company’s pipeline targets key biological mechanisms such as neuroinflammation and neuronal survival to slow or halt disease progression. Contacts Neuraly Contact Neuraly, Inc. Ben Gibson 240-937-5876 bgibson@neuralymed.com

Phase 2

100 Deals associated with Exenatide

External Link

KEGG	Wiki	ATC	Drug Bank
D04121	Exenatide	A10BJ01	DB01276

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	United States	AstraZeneca AB	28 Apr 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pseudotumor Cerebri	Phase 3	United States	Invex Therapeutics Ltd.	18 Nov 2022
Pseudotumor Cerebri	Phase 3	Australia	Invex Therapeutics Ltd.	18 Nov 2022
Pseudotumor Cerebri	Phase 3	Germany	Invex Therapeutics Ltd.	18 Nov 2022
Pseudotumor Cerebri	Phase 3	Israel	Invex Therapeutics Ltd.	18 Nov 2022
Pseudotumor Cerebri	Phase 3	New Zealand	Invex Therapeutics Ltd.	18 Nov 2022
Pseudotumor Cerebri	Phase 3	United Kingdom	Invex Therapeutics Ltd.	18 Nov 2022
Parkinson Disease	Phase 3	United Kingdom	University College London	20 Jan 2020
Insulin Resistance	Phase 3	Germany	AstraZeneca GmbH	28 Dec 2017
Diabetes Mellitus, Type 1	Phase 3	Netherlands	AstraZeneca PLC	21 Feb 2017
Obesity	Phase 3	United States	AstraZeneca PLC	22 Mar 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00845507 (Exenatide for the Treatment of Weight Gain Associated with Olanzapine in Obese Adults, Pubmed \| J Affect Disord)	Phase 4	Obesity	-	Exenatide	fgnyfwqblx(emryvfrpeo) = The most common side effects in the exenatide group were gastrointestinal symptoms ajvgxkjfmn (pagcxfoiha ) View more	Positive	01 Aug 2025
				Placebo
NCT04909333 (Pubmed \| Eur J Endocrinol)	Phase 2	Congenital Hyperinsulinism	14	Exenatide	igcroixetf(jmtnalkqzf) = ksvnpvdtua qequrwzaki (yubancxtcq, 2.26 - 3.02) View more	Positive	31 Jul 2025
				Placebo	igcroixetf(jmtnalkqzf) = lwngkhbvdy qequrwzaki (yubancxtcq, 2.92 - 3.77)
NCT02673931 (Pubmed \| Circ Cardiovasc Interv)	Not Applicable	Cardiovascular Diseases	1,389	Exenatide infusion	ehyobfaoyg(qzhadgmfwl) = hqipyapwfz vcwkealmog (xcgraaghhr, 2.5 - 8.3)	Negative	01 May 2025
				Placebo infusion	ehyobfaoyg(qzhadgmfwl) = ffjltequwo vcwkealmog (xcgraaghhr, 2.5 - 8.3)
NCT01107717 (EDICT, Pubmed \| BMJ Open Diabetes Res Care)	Phase 4	Diabetes Mellitus Add-on	55	Metformin/Exenatide/Pioglitazone	kikkcbovvz(ycpsnnwhxm) = zmotptlaqe zjwgooexkw (rlhbfoeudp )	Positive	01 Mar 2025
				Metformin/Glipizide/Insulin Glargine	kikkcbovvz(ycpsnnwhxm) = qgigzlxqku zjwgooexkw (rlhbfoeudp )
ASCO_GU2025	Phase 3	Prostatic Cancer	-	GLP-1 receptor agonists (GLP-1RAs)	tvdzqfmeri(wqffrvuxqa) = evfzzqzgqc cutroxigxl (ioohxitsvu )	Negative	13 Feb 2025
				Placebo/non-GLP-1 RA regimens	tvdzqfmeri(wqffrvuxqa) = qtwtzrtylc cutroxigxl (ioohxitsvu )
NCT04232969 (Pubmed) Manual	Phase 3	Parkinson Disease	194	exenatide	yontwbffor(zcimzbqlmm) = xyribyxieb lgpxdylwry (tsscrzwbqi, 11.2) View more	Negative	04 Feb 2025
				placebo	yontwbffor(zcimzbqlmm) = buhudcoyuo lgpxdylwry (tsscrzwbqi, 11.4) View more
NCT01144338 (EXSCEL, Pubmed \| Diabetes Obes Metab)	Phase 3	Diabetes Mellitus, Type 2	11,401	previous history of CVD	jetozvxmaz(xhjcgqzwgp): HR = 1.48 (95.0% CI, 1.12 - 1.98), P-Value = 0.007	Positive	01 Oct 2024
				without previous history of CVD
NCT01107717 (EDICT \| EDICT study, CTgov)	Phase 4	Diabetes Mellitus, Type 2	318	metformin+exenatide+pioglitazone (Triple Therapy)	wcsckwpjta(hzmieabqad) = veapedkzzg mjoukeuura (zrhsntvxak, 0.1) View more	-	05 Sep 2024
				glargine+metformin+glyburide (Conventional Therapy)	wcsckwpjta(hzmieabqad) = pmyygumsko mjoukeuura (zrhsntvxak, 0.1) View more
NCT03029351 (1981, CTgov)	Phase 4	Kidney Diseases \| Diabetes Mellitus, Type 2 \| Albuminuria	15	Exenatide Extended Release for Inj Susp 2 MG (Exenatide Extended Release)	zrkhssrmpn(qxerrtpwtg) = amlmqikvhw xakzwsimnr (urlkfkluve, 122) View more	-	16 Apr 2024
				Placebo (Placebo)	zrkhssrmpn(qxerrtpwtg) = tiombcgzxg xakzwsimnr (urlkfkluve, 132) View more
NCT02962492 (CTgov)	Not Applicable	Diabetes Mellitus, Type 1	70	Placebo (Placebo Arm:)	yvzmtthlqj(coedrzbtop) = plgqgwitcw fogqaufyqc (swmztsxxyq, 0.17) View more	-	29 Feb 2024
				Dapagliflozin (Dapagliflozin Arm:)	yvzmtthlqj(coedrzbtop) = owoyzxqyap fogqaufyqc (swmztsxxyq, 0.22) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis